Macrolides are reported to reduce exacerbation of chronic inflammatory respiratory disease, such as chronic obstructive pulmonary disease (COPD), and also show anti-inflammatory effects in vitro and in vivo. However, the anti-inflammatory efficacy of current macrolides is relatively weak. Here we found that a novel macrolide/fluoroketolide solithromycin (SOL) (CEM-101) showed superior anti-inflammatory effects in human monocytic U937 cells and peripheral blood mononuclear cells obtained from patients with COPD. In addition, SOL induced superior effects on cigarette smoke-induced airway inflammation in mice. Thus, SOL may be a promising anti-inflammatory and anti-microbial macrolide for the treatment of COPD in the future.
See article at J Pharmacol Exp Ther 2013, 345:76–84.
- Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics